今天biosensors放量大涨，有可能是第二个MIDAS?

bluej · 发表于 26-1-2013 22:09:18|来自：新加坡

ocbc说目标价1.69，可以当真么？

xkclzf · 发表于 26-1-2013 22:39:57|来自：新加坡

bluej 发表于 26-1-2013 22:09
ocbc说目标价1.69，可以当真么？

这些人说的目标价都不靠谱的
股价上去了, 他们就调高目标价
股价下跌了, 他们就调低目标价
关键是看公司有没有继续让更多人买入的潜力, 比如说高增长, 或者新产品获批等等!

bluej · 发表于 27-1-2013 08:04:24|来自：新加坡

xkclzf 发表于 26-1-2013 22:39
这些人说的目标价都不靠谱的
股价上去了, 他们就调高目标价
股价下跌了, 他们就调低目标价

应该也不全是这样吧。我看了往期的分析，他们在去年11月份以来就在这个价位有推荐这个股票，而11月份貌似还在跌的时候。你说的比如新产品退出，新市场准入等等，当然会刺激股价，他们也肯定会调高目标价的，也不矛盾吧。

xkclzf · 发表于 28-1-2013 22:19:49|来自：新加坡

Biosensors Receives CE Mark Approval for BioFreedom™

Singapore, 28 January 2013 – Biosensors International Group, Ltd. (“Biosensors” or the “Company”,

Bloomberg: BIG SP Reuters: BIOS.SI SGX: B20), a developer, manufacturer and marketer of

innovative medical devices, today announced CE Mark approval for its polymer-free drug-coated

stent (DCS), BioFreedom™.

BioFreedom represents the latest development in Biosensors’ stent technology, featuring a microstructured abluminal surface which permits the controlled release of Biolimus A9™ (BA9™) without

the use of a polymer. BA9 is a highly lipophilic anti-restenotic drug developed by Biosensors

specifically for use with stents.

CE Mark approval for BioFreedom was supported by strong data from the BioFreedom First in Man

study. In this study BioFreedom was compared to Boston Scientific’s Taxus™ Liberté™ drug-eluting

stent (DES). At 12 months, BioFreedom demonstrated equivalent efficacy, measured by in-stent late

lumen loss, compared with Taxus Liberté, with a trend towards superiority. Median in-stent late

lumen loss in patients receiving BioFreedom was reduced to 0.17 mm as compared with a median instent late lumen loss of 0.35 mm in the Taxus Liberté group. Three year clinical results, presented at

the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in October 2012, showed

similar rates of MACE (Major Adverse Cardiac Events) between BioFreedom and Taxus Liberté, with

no evidence of stent thrombosis in either group.

To further evaluate BioFreedom in a larger patient population, Biosensors recently announced

initiation of enrolment in LEADERS FREE, the world’s first prospective, randomised double-blind trial

between a DCS and bare-metal stent (BMS), exclusively involving patients at high risk of bleeding.

The study has been designed to confirm that BioFreedom is as safe as a BMS in this patient group,

and can deliver the anti-restenotic benefit of a DES, with only a one-month course of dual antiplatelet therapy administered to all patients.

This trial will provide additional data to support the launch of BioFreedom in select markets during

2013. The full commercial launch is currently anticipated during 2014.